Article

Former Alcon executive becomes Iridex president/CEO

Barry G. Caldwell joins Iridex Corp. as president and chief executive officer and as a member of the board of directors. He succeeds Theodore A. Boutacoff, who has been elected chairman of the board for Iridex.

Caldwell worked for Alcon Laboratories for more than 2 decades in numerous executive positions, including vice president of Alcon Canada as well as vice president and general manager of Alcon’s U.S. Surgical Division.

“His successful track record includes achievements in operating performance, strategic planning, mergers and acquisitions, and executing strategic initiatives-which resulted in profitable revenue growth,” Boutacoff said.

“With more than 30 years of experience in the ophthalmic sector and more than 20 years of tenure at Alcon, Barry has well-established relationships with physicians, industry executives, and key regulatory and legislative opinion leaders that will be beneficial to Iridex,” Boutacoff added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.